%0 Journal Article
%T ¦Â
%A Ambrogio Fassina
%A Elena Fasanaro
%A Ennio Nardello
%A Fabio Biagio La Torre
%A Giancarlo Ottaviano
%A Gino Marioni
%A Lorenzo Nicol¨¨
%A Roberto Di Carlo
%A Rocco Cappellesso
%A Rosario Marchese-Ragona
%A Tiziana Sanavia
%J The International Journal of Biological Markers
%@ 1724-6008
%D 2019
%R 10.1177/1724600818813621
%X The novel primary end-point of the present study was to ascertain ¦Â-arrestin-1 expression in a cohort of consecutive patients with laryngeal squamous cell carcinoma (LSCC) with information available on their cigarette-smoking habits. A secondary end-point was to conduct a preliminary clinical and pathological investigation into the possible role of ¦Â-arrestin-1 in the epithelial-to-mesenchymal transition (EMT), identified by testing for E-cadherin, Zeb1, and Zeb2 expression, in the setting of LSCC. The expression of ¦Â-arrestin-1, E-cadherin, zeb1, and zeb2 was ascertained in 20 consecutive LSCCs. Statistical analysis showed no significant associations between ¦Â-arrestin-1 and EMT (based on the expression of E-cadherin, Zeb1, and Zeb2). The combined effect of nicotine and ¦Â-arrestin-1 was significantly associated with a shorter disease-free survival (P=0.01) in our series of LSCC. This latter result was also confirmed in an independent, publicly available LSCC cohort (P=0.047). Further investigations on larger series (ideally in prospective settings) are needed before we can consider closer follow-up protocols and/or more aggressive treatments for patients with LSCC and a combination of nicotine exposure and ¦Â-arrestin-1 positivity in tumor cells at the time of their diagnosis. Further studies on how ¦Â-arrestin functions in cancer via different signaling pathways might reveal potential targets for the treatment of even advanced laryngeal malignancies
%K Laryngeal carcinoma
%K ¦Â-arrestin-1
%K epithelial-to-mesenchymal transition
%K nicotine
%K prognosis
%U https://journals.sagepub.com/doi/full/10.1177/1724600818813621